Despite a recent rally, General Electric (NYSE:GE) stock has shed more than two-thirds of its value since the beginning of 2017. Furthermore, several vocal analysts believe that the stock is still overvalued and could fall to $6 or even lower.
Bearish analysts have a number of valid concerns about GE, particularly related to its weak balance sheet and the plunging profitability of its power segment. That said, these analysts seem to be drastically undervaluing the company’s most profitable business: GE Aviation. GE Aviation already accounts for the majority of the conglomerate’s earnings, and it is poised to continue growing rapidly over the next decade.
Another excellent year in the books
Most of General Electric’s businesses struggled in 2018, but GE Aviation had an incredible year. For the full year, aviation segment revenue rose 13% to $30.6 billion. Segment profit grew at an even faster rate, surging 20% to $6.5 billion.
While the aviation division only accounted for about a quarter of General Electric’s revenue in 2018, it provided 60% of the company’s industrial segment profit. The aviation business will only grow in importance over the next year or two, as GE plans to shed its oil and gas, transportation, and healthcare segments — and most likely its lighting business — through asset sales, spinoffs, and share sales. Collectively, these segments that are likely to be sold or spun off generated $4.8 billion of profit on $48.3 billion of revenue last year.
Top Value Stocks To Buy Right Now: Visteon Corporation(VC)
Advisors’ Opinion:
- [By Joseph Griffin]
Investors bought shares of Visteon Corp (NYSE:VC) on weakness during trading hours on Friday. $25.19 million flowed into the stock on the tick-up and $13.69 million flowed out of the stock on the tick-down, for a money net flow of $11.50 million into the stock. Of all companies tracked, Visteon had the 19th highest net in-flow for the day. Visteon traded down ($2.64) for the day and closed at $112.62
- [By Stephan Byrd]
VirtualCoin (CURRENCY:VC) traded flat against the US dollar during the twenty-four hour period ending at 16:00 PM ET on June 19th. One VirtualCoin coin can currently be purchased for approximately $0.0119 or 0.00000144 BTC on exchanges. During the last seven days, VirtualCoin has traded 33.1% lower against the US dollar. VirtualCoin has a market cap of $120,251.00 and approximately $0.00 worth of VirtualCoin was traded on exchanges in the last 24 hours.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on Visteon (VC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
Get a free copy of the Zacks research report on Visteon (VC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
VirtualCoin (CURRENCY:VC) traded flat against the US dollar during the 1 day period ending at 21:00 PM ET on August 16th. VirtualCoin has a total market capitalization of $120,251.00 and approximately $0.00 worth of VirtualCoin was traded on exchanges in the last 24 hours. One VirtualCoin coin can currently be purchased for about $0.0119 or 0.00000144 BTC on cryptocurrency exchanges. Over the last seven days, VirtualCoin has traded down 33.1% against the US dollar.
- [By Joseph Griffin]
VirtualCoin (CURRENCY:VC) traded flat against the dollar during the 24 hour period ending at 19:00 PM E.T. on August 14th. One VirtualCoin coin can now be bought for $0.0119 or 0.00000144 BTC on popular cryptocurrency exchanges. VirtualCoin has a market cap of $120,251.00 and approximately $0.00 worth of VirtualCoin was traded on exchanges in the last day. During the last seven days, VirtualCoin has traded down 33.1% against the dollar.
Top Value Stocks To Buy Right Now: Dynavax Technologies Corporation(DVAX)
Advisors’ Opinion:
- [By Ethan Ryder]
Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reissued by research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday. They presently have a $27.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would suggest a potential upside of 67.70% from the stock’s current price.
- [By Logan Wallace]
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
Get Dynavax Technologies alerts:
Dynavax Technologies Co. (DVAX) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com) Earnings per share (EPS) in the Spotlight – Dynavax Technologies Corporation (NASDAQ: DVAX) (stocksmarketcap.com) Is the Stock Safe to Invest? – Dynavax Technologies Corporation (NASDAQ:DVAX) (nasdaqjournal.com) Investor’s Watch List: Dynavax Technologies Corporation (DVAX) (nasdaqplace.com) You Need to Watch this stock? Dynavax Technologies Corporation (DVAX) (connectinginvestor.com)
DVAX has been the topic of several analyst reports. Cantor Fitzgerald set a $27.00 price objective on Dynavax Technologies and gave the company a “buy” rating in a research note on Wednesday, May 16th. ValuEngine lowered Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, May 1st. BidaskClub downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Sunday, April 22nd. Finally, JPMorgan Chase & Co. raised Dynavax Technologies from a “neutral” rating to an “overweight” rating and set a $25.00 target price on the stock in a report on Thursday, May 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. Dynavax Technologies currently has a consensus rating of “Buy” and an average target price of $24.67.
- [By Stephan Byrd]
Dynavax Technologies (NASDAQ:DVAX) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Thursday.
- [By George Budwell]
Shares of Dynavax Technologies (NASDAQ:DVAX), a vaccine and immuno-oncology specialist, dropped by 15.9% last month, according to data from S&P Global Market Intelligence. What sparked this sell-off?
- [By William Romov]
If a biotech stock’s clinical trial results are positive, or receives a nod of approval from the FDA, then the stock can soar. For example, last year Dynavax Technologies Corp. (Nasdaq: DVAX) shares more than quadrupled between May 31 and Oct. 5, when it climbed 337.6%, from $5.50 to $24.07.
Top Value Stocks To Buy Right Now: Bridgeline Digital, Inc.(BLIN )
Advisors’ Opinion:
- [By Stephan Byrd]
Get a free copy of the Zacks research report on Bridgeline Digital (BLIN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
Here are some of the headlines that may have impacted Accern’s rankings:
Get Bridgeline Digital alerts:
Zacks: Bridgeline Digital Inc (BLIN) Given Average Recommendation of “Buy” by Analysts (americanbankingnews.com) Bridgeline Digital Shares Shoot Ahead on New Customer (baystreet.ca) Bridgeline Digital sees shares soar after its web analytics software welcomes a new user (proactiveinvestors.com) Procurement Services Provider Chooses the Bridgeline Unbound Insights Product for Web Analytics Solution (finance.yahoo.com)
BLIN traded down $0.12 during trading on Tuesday, hitting $1.04. 455,300 shares of the company’s stock traded hands, compared to its average volume of 548,370. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 0.53. Bridgeline Digital has a 12-month low of $0.79 and a 12-month high of $4.45. The company has a market cap of $4.92 million, a price-to-earnings ratio of -4.33 and a beta of 0.14.
- [By Ethan Ryder]
Headlines about Bridgeline Digital (NASDAQ:BLIN) have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bridgeline Digital earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the software maker an impact score of 46.3358005969314 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
- [By Alexander Bird]
Here are the top performers from last week…
Penny Stock Current Share Price Last Week’s Gain
Staffing 360 Solutions Inc. (Nasdaq: STAF) $2.58 96.35%
IZEA Inc. (Nasdaq: IZEA) $1.65 85.19%
ShiftPixy Inc. (Nasdaq: PIXY) $3.35 78.38%
MER Telemanagement Solutions Ltd. (Nasdaq: MTSL) $3.31 41.07%
IsoRay Inc. (NYSE: ISR) $0.60 38.64%
TransGlobe Energy Corp. (Nasdaq: TGA) $3.74 37.76%
Actinium Pharmaceuticals Inc. (OTCMKTS: ATNM) $0.27 26.31%
Blonder Tongue Labs Inc. (NYSE: BDR) $1.56 24.58%
Bridgeline Digital Inc. (Nasdaq: BLIN) $1.51 24.51%
Cel-Sci Corp. (NYSE: CVM) $0.91 24.03%While these penny stocks generated strong returns last week, they’re unlikely to produce the same level of profit again anytime soon.